Medimaps Group is a Swiss company that provides advanced medical deep-tech and AI imaging software for comprehensive bone microarchitecture assessment. This is a crucial aspect of bone strength and is essential for evaluating bone health to prevent fracture.

The company was founded by medical practitioners and clinical researchers with the goal to transform complex clinical needs into straightforward routine solutions that seamlessly integrate the healthcare professionals’ workflow.
​
Medimaps Group’s flagship product, TBS Osteo, powered by TBS insight AI-ready technology, has been widely adopted for clinical use in 60 countries and more than 3 million procedures are performed every year. In January 2022, TBS Osteo achieved a significant milestone by being approved for reimbursement by Medicare in the USA under Category 1, which indicates that the procedure meets strict criteria for clinical acceptance, efficacy and widely use.